How do I read and understand my MDS pathology report

Understanding Your MDS Pathology Report

I'm glad you're taking an active role in understanding your [ID removed] A pathology report is one of the most important documents in your MDS diagnosis, and I'll help you break down what you're reading.

The Main Sections of an MDS Pathology Report

1. SPECIMEN INFORMATION

This section identifies what was tested:

• Type of sample: Usually bone marrow aspirate (liquid sample) and/or bone marrow biopsy (tissue sample)
• Collection date: When the sample was taken
• Clinical history: Brief notes about why the test was ordered

What to look for: Make sure the specimen type matches what your doctor said they were collecting.

---

2. MORPHOLOGY (What the cells look like)

This describes the appearance of your blood and bone marrow cells under the microscope:

Key findings to understand:

• Blast percentage: The percentage of immature blood cells (blasts). In MDS, this is crucial because it helps determine disease severity. According to the NCCN Guidelines for MDS, blast percentage is one of the main factors doctors use to classify your disease and decide on treatment.

  • Normal: <5% blasts
  • Lower-risk MDS: Usually <10% blasts
  • Higher-risk MDS: 10-19% blasts
  • AML (acute myeloid leukemia): ≥20% blasts

• Dysplasia: Abnormal-looking cells. The report may describe dysplasia in specific cell lines:

  • Erythroid dysplasia (red blood cell abnormalities)
  • Myeloid dysplasia (white blood cell abnormalities)
  • Megakaryocytic dysplasia (platelet-forming cell abnormalities)

• Ring sideroblasts (RS): Red blood cells with iron deposits visible as rings. This is important because according to NCCN Guidelines, SF3B1 mutations are strongly associated with ring sideroblasts, and this finding affects treatment decisions. If you have ≥15% ring sideroblasts (or ≥5% with an SF3B1 mutation), your doctor may recommend specific treatments like imetelstat or luspatercept.

• Cellularity: Whether your bone marrow is hypocellular (too few cells), normocellular (normal amount), or hypercellular (too many cells)

---

3. CYTOGENETICS (Chromosome analysis)

This section reports any abnormalities in your chromosomes:

What to look for:

• Karyotype: A visual map of your chromosomes. Normal is 46,XX or 46,XY
• Common MDS abnormalities:
  • del(5q) (deletion of chromosome 5): Often associated with better prognosis and specific treatment options (lenalidomide)
  • del(7q) or -7 (loss of chromosome 7): Associated with poorer prognosis
  • Trisomy 8 (+8): Extra chromosome 8
  • Complex karyotype: 3 or more abnormalities (generally indicates higher risk)
  • Normal karyotype: No visible abnormalities

Why it matters: According to NCCN Guidelines, cytogenetic findings are critical for risk stratification and determining which treatments your doctor will recommend.

---

4. MOLECULAR TESTING (Gene mutations)

This is increasingly important in MDS diagnosis. The report lists specific gene mutations found in your cells.

Key MDS-related genes (according to NCCN Guidelines):

Genes associated with BETTER prognosis:

• SF3B1: Found in 20-30% of MDS cases, strongly associated with ring sideroblasts and more favorable outcomes

Genes associated with WORSE prognosis:

• TP53: Associated with poor prognosis, especially with complex karyotypes
• ASXL1: Independently associated with poor prognosis
• RUNX1: Independently associated with poor prognosis
• EZH2: Associated with poor prognosis
• BCOR/BCORL1: Associated with poor prognosis
• SRSF2, U2AF1, ZRSR2: Splicing factor mutations associated with poor prognosis

Other important mutations:

• DNMT3A, TET2: Common in MDS (12-25%), but can also occur in aging without disease
• IDH1/IDH2: More frequent in AML but can occur in MDS; associated with poor prognosis
• WT1: Associated with poor prognosis

What the numbers mean: You may see "VAF" (variant allele frequency) listed—this is the percentage of cells carrying the mutation. Higher VAF generally suggests a larger clone of abnormal cells.

---

5. FLOW CYTOMETRY (Cell analysis by laser)

This uses special staining to identify and count different cell types:

• Abnormal populations: Whether there are unusual cell populations present
• Blast percentage: Another way to count immature cells
• Immunophenotype: The specific markers on cells that help classify the disease

---

6. DIAGNOSIS/IMPRESSION

This is the pathologist's summary, typically including:

• MDS classification (according to WHO 2022 criteria):

  • MDS with single lineage dysplasia (MDS-SLD)
  • MDS with multilineage dysplasia (MDS-MLD)
  • MDS with ring sideroblasts (MDS-RS)
  • MDS with excess blasts (MDS-EB-1 or MDS-EB-2)
  • MDS with isolated del(5q)
  • MDS, unclassifiable (MDS-U)

• Risk category: Your disease may be classified as:

  • Very low-risk
  • Low-risk
  • Intermediate-risk
  • High-risk

According to NCCN Guidelines, doctors use the IPSS-M (Integrated Prognostic Scoring System) calculator to determine your specific risk category, which combines cytogenetics, blast percentage, and molecular mutations.

---

Questions to Ask Your Doctor About Your Report

1. What is my blast percentage, and what does that tell us about my disease stage?

2. Do I have any cytogenetic abnormalities, and what do they mean for my prognosis?

3. What gene mutations were found, and how do they affect my treatment options?

4. What is my IPSS-M risk score, and what does that mean for my treatment plan?

5. Do I have ring sideroblasts, and if so, what percentage? (This affects whether you're a candidate for specific drugs like imetelstat or luspatercept)

6. Based on all these findings together, what treatment do you recommend, and why?

7. How often should I have follow-up testing, and what will you be monitoring?

8. Are there any clinical trials that might be appropriate for my specific mutation profile?

---

Important Context

According to NCCN Guidelines, it's important to understand that:

• No single finding is diagnostic by itself: Your pathology report is one piece of the puzzle. Your doctor considers your symptoms, blood counts, and clinical history together with these findings.

• Mutations can occur without disease: Some mutations listed (like DNMT3A, TET2, ASXL1) can occur in healthy aging and don't automatically mean you have MDS. The complete clinical picture matters.

• Risk changes over time: Your disease may progress, so repeat bone marrow biopsies help track changes in blast percentage, mutations, and cytogenetics.

---

Next Steps

If your pathology report is available, I'd be happy to help you understand specific findings. You can share:

• Your blast percentage
• Any cytogenetic abnormalities
• Gene mutations listed
• Your risk category (if stated)

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.